Drug companies on verge of sinking longtime Democratic priority [history rewrite]

The Hill ^ | 20 September 2021 | KARL EVERS-HILLSTROM

[blueplum]

The pharmaceutical industry is on the verge of defeating a major Democratic proposal that would allow the federal government to negotiate drug prices.

Speaker Nancy Pelosi (D-Calif.) can afford only three defections when the House votes on a sweeping $3.5 trillion spending package, but Reps. Scott Peters (D-Calif.), Kurt Schrader (D-Ore.) and Kathleen Rice (D-N.Y.) last week voted to block the drug pricing bill from advancing out of the Energy and Commerce Committee. Rep. Stephanie Murphy (D-Fla.) voted against advancing the tax portion of the legislation in the House Ways and Means Committee.

All told, the number of House Democrats who have concerns about the drug pricing bill is in the double digits...

/...The bill at the center of the fight, H.R. 3, would allow Medicare to negotiate the price of prescription drugs by tying them to the lower prices paid by other high-income countries.

[blueplum]

the drug bill part of H.R. 3 is now claimed as a brainchild of Pelosi. Even though it is a carbon copy of the plan Trump authored. Repackaged with a Pelosi Priority Bow, the Dems still reject the plan. Once again making this a midterm platform plank.

[packagingguy]

So President Trump worked to lower the prices of prescription drugs, insulin for example, and the American public punished him at the polls (or didn’t). Either Americans are stupid or the Democrats cheated. One or the other.

[cgbg]

Dead people voted in favor of higher prescription drug prices—easy peasy.

[Brian Griffin]

“H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act
116th Congress (2019-2020)
Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] (Introduced 09/19/2019)”

https://www.congress.gov/bill/116th-congress/house-bill/3